CRL · 10-Q · 2026Q2 · Full report
Liquidity and Debt Position
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 79 · Surprise 66 · In source text
Cash and cash equivalents totaled $192.0 million at June 27, 2026, down from $213.8 million at December 27, 2025. Total debt increased to $2.620 billion from $2.117 billion, including $1.120 billion outstanding under the revolving facility versus $616.5 million at year-end. The company generated $519.3 million of net Credit Facility proceeds during the first half of 2026 and had a $2.0 billion revolving facility maturing in December 2029 with no scheduled payment before maturity. Management stated that existing funds, operating cash flow, and financing access were sufficient to fund operations for the foreseeable future.
Key facts
- As of June 27, 2026, $105.0 million of deferred consideration for the Cambodian NHP Supplier acquisition remains to be paid and is recorded in Accrued liabilities. source
- The Credit Facility provides for up to $2.0 billion of multi-currency revolving credit and has a maturity date of December 2029 with no required scheduled payment before that date. source
- Net proceeds of $519.3 million from the Credit Facility were received in the six months ended June 27, 2026. source
- Amounts outstanding under the Credit Facility and Senior Notes as of June 27, 2026: Revolving facility $1,120,293; 4.25% Senior Notes due 2028 $500,000; 3.75% Senior Notes due 2029 $500,000; 4.00% Senior Notes due 2031 $500,000; Total $2,620,293 (in thousands). source
- The PathoQuest acquisition was funded through a combination of available cash and proceeds from the Credit Facility. source
- Proceeds from sale of businesses and assets, net for the six months ended June 27, 2026: $176,563 thousand. source
- Net cash provided by (used in) financing activities for the six months ended June 27, 2026: $183,063 thousand, including proceeds from long-term debt and revolving credit facility of $1,265,258 thousand and payments on long-term debt, revolving credit facility and finance lease obligations of $(745,927) thousand. source
- Net proceeds of $519.3 million, primarily from the Credit Facility, were a driver of net cash provided by financing activities in the six months ended June 27, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | realized | +6.9% | Net proceeds of $519.3 million from the Credit Facility were received in the six months ended June 27, 2026. |
| liability | negative | realized | -6.9% | Net proceeds of $519.3 million from the Credit Facility were received in the six months ended June 27, 2026. |
| cash | negative | realized | -5.0% | Net cash used in investing activities for the six months ended June 27, 2026: $(379,748) thousand, including acquisition of businesses and… |
| cash | positive | realized | +2.4% | Net cash provided by (used in) financing activities for the six months ended June 27, 2026: $183,063 thousand, including proceeds from… |
| cash | positive | realized | +2.3% | Proceeds from sale of businesses and assets, net for the six months ended June 27, 2026: $176,563 thousand. |
| liability | negative | realized | -1.4% | As of June 27, 2026, $105.0 million of deferred consideration for the Cambodian NHP Supplier acquisition remains to be paid and is… |
| liability | negative | realized | — | Amounts outstanding under the Credit Facility and Senior Notes as of June 27, 2026: Revolving facility $1,120,293; 4.25% Senior Notes due… |
| cash | negative | realized | — | The PathoQuest acquisition was funded through a combination of available cash and proceeds from the Credit Facility. |
| liability | negative | realized | — | The PathoQuest acquisition was funded through a combination of available cash and proceeds from the Credit Facility. |